Colorectal Cancer Remains A Formidable Global Health Challenge

Mariam Abulgith^1, , Salhah Alshihri¹, Hassan Al mnamis¹, Ohud Asiri¹, Nourah Shaio¹ and Fatimah Alqisi¹

¹Regional Laboratory, Ministry of Health, Riyadh, Saudi Arabia

Cite this paper:
Mariam Abulgith, Salhah Alshihri, Hassan Al mnamis, Ohud Asiri, Nourah Shaio and Fatimah Alqisi. Colorectal Cancer Remains A Formidable Global Health Challenge. American Journal of Medical and Biological Research. 2024; 12(2):49-60. doi: 10.12691/ajmbr-12-2-3

Abstract

Colorectal cancer remains a formidable global health challenge, characterized by high recurrence rates and poor prognosis. This study introduces a novel Recurrence Related Gene Signature (RRGS), designed to predict therapy response and enhance prognostic accuracy in colorectal cancer. Through analysis of the GSE17536 cohort, we identified 79 differentially expressed genes (DEGs) between recurrent and non-recurrent cases, comprising 54 upregulated and 25 downregulated genes. Pathway analysis revealed that upregulated genes were enriched in cancer progression-related pathways, while downregulated genes were associated with immune-related processes. Leveraging these findings, we developed the RRGS using LASSO regression, resulting in an innovative 11-gene model with robust diagnostic and prognostic capabilities. Notably, the RRGS demonstrated significant predictive value for both overall survival and disease-free survival across multiple datasets, with higher RRGS scores correlating with advanced tumor stages and poorer outcomes, particularly in post-chemotherapy patients. This predictive power highlights the RRGS's potential in guiding personalized treatment strategies. Furthermore, we identified STC1 as a critical component of the RRGS, playing a significant role in tumor progression and immune evasion. Through rigorous in vitro and in vivo experiments we confirmed that STC1 knockdown substantially reduced cell proliferation and metastasis, emphasizing its potential as a therapeutic target. This comprehensive study not only elucidates the molecular mechanisms driving colorectal cancer recurrence but also introduces a powerful tool for enhancing prognostic accuracy and personalizing therapeutic interventions.

Keywords:
Colorectal cancer Recurrence Recurrence risk gene signature STC1 Prognostic biomarkers

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends in pharmacological sciences. 2023; 44: 222-36.
[2]	Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M. et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Molecular cancer. 2022; 21: 144.
[3]	Eng C, Jácome AA, Agarwal R, Hayat MH, Byndloss MX, Holowatyj AN. et al. A comprehensive framework for early-onset colorectal cancer research. The Lancet Oncology. 2022; 23: e116-e28.
[4]	Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J. et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2023; 34: 10-32.
[5]	Patel SG, Dominitz JA. Screening for Colorectal Cancer. Annals of internal medicine. 2024; 177: Itc49-itc64.
[6]	Underwood PW, Ruff SM, Pawlik TM. Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. Cells. 2024; 13: 245.
[7]	Huang X, Lin Q, Lu L, Li M, Tang D. In(2)O(3)/CdIn(2)S(4) heterojunction-based photoelectrochemical immunoassay of carcinoembryonic antigen with enzymatic biocatalytic precipitation for signal amplification. Analytica chimica acta. 2022;1228:340358
[8]	Huang L, Zeng Y, Liu X, Tang D. Pressure-Based Immunoassays with Versatile Electronic Sensors for Carcinoembryonic Antigen Detection. ACS applied materials & interfaces. 2021; 13: 46440-50.
[9]	Zeng R, Tang D. Magnetic bead-based photoelectrochemical immunoassay for sensitive detection of carcinoembryonic antigen using hollow cadmium sulfide. Talanta. 2020; 219: 121215.
[10]	Asano H, Fukano H, Takagi M, Takayama T. Risk factors for the recurrence of stage II perforated colorectal cancer: A retrospective observational study. Asian journal of surgery. 2023;46:201-6
[11]	Vrieling A, Kampman E. The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature. The American journal of clinical nutrition. 2010; 92: 471-90.
[12]	Fujii T, Tabe Y, Yajima R, Yamaguchi S, Tsutsumi S, Asao T. et al. Extracapsular invasion as a risk factor for disease recurrence in colorectal cancer. World journal of gastroenterology. 2011; 17: 2003-6.
[13]	Qiu Z, Shu J, Tang D. Bioresponsive Release System for Visual Fluorescence Detection of Carcinoembryonic Antigen from Mesoporous Silica Nanocontainers Mediated Optical Color on Quantum Dot-Enzyme-Impregnated Paper. Analytical chemistry. 2017; 89: 5152-60.
[14]	Tamura S, Oshima T, Yoshihara K, Kanazawa A, Yamada T, Inagaki D. et al. Clinical significance of STC1 gene expression in patients with colorectal cancer. Anticancer research. 2011; 31: 325-9.
[15]	Yeung HY, Lai KP, Chan HY, Mak NK, Wagner GF, Wong CK. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. Endocrinology. 2005;146:4951-60
[16]	Shirakawa M, Fujiwara Y, Sugita Y, Moon JH, Takiguchi S, Nakajima K. et al. Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncology reports. 2012; 27: 940-6.
[17]	Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J. et al. Stanniocalcin 1 and ovarian tumorigenesis. Journal of the National Cancer Institute. 2010; 102: 812-27.
[18]	Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL. et al. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology. 2012; 142: 562-71.e2.
[19]	Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS medicine. 2013; 10: e1001453.
[20]	Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research. 2000; 28: 27-30.
[21]	Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic acids research. 2016; 44: W90-7.
[22]	Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell systems. 2015; 1: 417-25.
[23]	Cox DR, Battey HS. Large numbers of explanatory variables, a semi-descriptive analysis. Proceedings of the National Academy of Sciences of the United States of America. 2017;114:8592-5
[24]	Liu CJ, Hu FF, Xie GY, Miao YR, Li XW, Zeng Y. et al. GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Briefings in bioinformatics. 2023; 24:bbac558.
[25]	Haria PD, Baheti AD, Palsetia D, Ankathi SK, Choudhari A, Guha A. et al. Follow-up of colorectal cancer and patterns of recurrence. Clinical radiology. 2021; 76: 908-15.
[26]	Loft M, To YH, Gibbs P, Tie J. Clinical application of circulating tumour DNA in colorectal cancer. The lancet Gastroenterology & hepatology. 2023;8:837-52
[27]	Zhou H, Zhu L, Song J, Wang G, Li P, Li W. et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Molecular cancer. 2022; 21: 86.
[28]	Song Y, Deng Z, Sun H, Zhao Y, Zhao R, Cheng J. et al. Predicting tumor repopulation through the gene panel derived from radiation resistant colorectal cancer cells. Journal of translational medicine. 2023;21:390
[29]	Aiello NM, Maddipati R, Norgard RJ, Balli D, Li J, Yuan S. et al. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Developmental cell. 2018;45:681-95.e4
[30]	Liu Y, Fang X, Wang Q, Xiao D, Zhou T, Kang K. et al. SMC1A facilitates gastric cancer cell proliferation, migration, and invasion via promoting SNAIL activated EMT. BMC gastroenterology. 2023; 23: 268.
[31]	Bao Y, Wang L, Shi L, Yun F, Liu X, Chen Y. et al. Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer. Cellular & molecular biology letters. 2019; 24: 38.
[32]	Fodde R. The APC gene in colorectal cancer. European journal of cancer (Oxford, England: 1990). 2002; 38: 867-71.
[33]	Chang AC, Jellinek DA, Reddel RR. Mammalian stanniocalcins and cancer. Endocrine-related cancer. 2003; 10: 359-73.
[34]	Chang AC, Doherty J, Huschtscha LI, Redvers R, Restall C, Reddel RR. et al. STC1 expression is associated with tumor growth and metastasis in breast cancer. Clinical & experimental metastasis. 2015; 32: 15-27.
[35]	Ren Z, Xu Z, Chang X, Liu J, Xiao W. STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop. Pharmacological research. 2024; 204: 107218.
[36]	He LF, Wang TT, Gao QY, Zhao GF, Huang YH, Yu LK. et al. Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells. Journal of biomedical science. 2011; 18: 39.
[37]	Luo M, Wang X, Wu S, Yang C, Su Q, Huang L. et al. A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal. Signal transduction and targeted therapy. 2023; 8: 312.